University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham B18 7QH, UK.
Expert Opin Pharmacother. 2010 Mar;11(4):685-7. doi: 10.1517/14656560903530691.
Oral anticoagulants such as warfarin have been used widely for the treatment of venous thromboembolism and stroke prevention in atrial fibrillation (AF) patients. Warfarin has significant limitations and also requires frequent monitoring. Thus, there is an unmet need, with the quest for alternative oral anticoagulants with stable pharmacokinetics and pharmacodynamics that do not need monitoring. The paper under evaluation provides us with up-to-date information on the safety and efficacy of a new oral anticoagulant, dabigatran, compared with warfarin for stroke prevention in AF patients.
口服抗凝剂如华法林被广泛用于治疗静脉血栓栓塞和预防心房颤动（AF）患者的中风。华法林有显著的局限性，也需要经常监测。因此，存在着一种未满足的需求，即寻找具有稳定药代动力学和药效动力学且不需要监测的替代口服抗凝剂。正在评估的论文为我们提供了有关新型口服抗凝剂达比加群与华法林预防 AF 患者中风的安全性和疗效的最新信息。
